IPM514

IPM514 is an investigational therapeutic vaccine currently in early clinical development for the treatment of esophageal squamous cell carcinoma (ESCC). The drug is being evaluated in a Phase 1 open-label, multicenter study to assess its safety, tolerability, pharmacokinetics, and preliminary efficacy. The trial includes several cohorts: a dose escalation phase with IPM514 monotherapy; a dose expansion phase where it is combined with an anti-PD-1 antibody (notably tislelizumab); and a neoadjuvant therapy cohort combining IPM514 with anti-PD-1 antibody plus cisplatin and paclitaxel. The primary indication under investigation is ESCC in patients who have failed first-line treatment or are candidates for neoadjuvant therapy prior to surgery. Mechanistic details such as molecular targets or precise mode of action have not been disclosed in public sources as of June 2025[1][2][3][5].